1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,540 | 4,620 | 19:04 | |
| 4,540 | 4,620 | 19:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock? | 1 | Zacks | ||
| Mi | Cytek auf Morgan Stanley Konferenz: Wachstum gewinnt an Breite, Europe bleibt schwach | 1 | Investing.com Deutsch | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 09.09. | Sysmex Europe SE and Cytek Biosciences, Inc. Collaborate to Expand Access to Advanced Clinical Flow Cytometry | 644 | GlobeNewswire (Europe) | FREMONT, Calif., and HAMBURG, Germany, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sysmex Europe SE, a leader in diagnostic and healthcare solutions, and Cytek Biosciences, Inc. (Nasdaq: CTKB), a leader in spectral... ► Artikel lesen | |
| 09.09. | Cytek's (CTKB) Instruments Keep Selling While Losses Keep Growing | 4 | Insider Monkey | ||
| 03.09. | Cytek Biosciences, Inc.: Cytek Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS | 1 | GlobeNewswire (USA) | ||
| 24.08. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Cytek Biosciences: Teilsieg im Patentstreit - dennoch 56 Millionen US-Dollar Schadenersatz | 2 | Investing.com Deutsch | ||
| 21.08. | Cytek Biosciences wins on three of four patent claims | 3 | Investing.com | ||
| 21.08. | Cytek Biosciences, Inc.: Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding | 628 | GlobeNewswire (Europe) | FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (Nasdaq: CTKB), a leading cell analysis solutions company, today announced... ► Artikel lesen | |
| 12.08. | Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments | 2 | pulse2.com | ||
| 06.08. | Cytek raises 2026 revenue outlook to $207M-$212M as it rolls out Borealis and Aurora Evo automation | 2 | Seeking Alpha | ||
| 05.08. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 22.07. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 15.07. | Cytek Biosciences, Inc.: Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement | 1 | GlobeNewswire (USA) | ||
| 15.07. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Cytek Biosciences, Inc.: Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 | 1 | GlobeNewswire (USA) | ||
| 02.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Earnings Call Transkript: Cytek Biosciences meldet Umsatzwachstum für Q1 2026, verfehlt aber Gewinnprognose | 1 | Investing.com Deutsch |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,008 | +53,85 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 2,510 | +2,87 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| CLINUVEL | 5,126 | +0,79 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| EDITAS MEDICINE | 2,420 | +2,98 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,596 | +1,42 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,662 | +1,84 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| ARBUTUS BIOPHARMA | 4,320 | -0,92 % | Arbutus Biopharma Corp-Aktie im Check am 17.09. (08:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| ASEP MEDICAL | 0,060 | 0,00 % | ASEP Medical Holdings Inc (2): ASEP to issue 2.88 million shares for debt of $288,500 | ||
| CELLECTAR BIOSCIENCES | 2,400 | +0,42 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,187 | -0,84 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| ALDEYRA | 1,160 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 17,405 | +1,34 % | Denali Therapeutics: Markteinführung von Avlayah gewinnt an Fahrt | ||
| ABCELLERA BIOLOGICS | 10,900 | -0,18 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 24,570 | -1,36 % | Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ | Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity... ► Artikel lesen | |
| AC IMMUNE | 2,300 | -0,22 % | AC Immune SA: AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe... ► Artikel lesen |
Das Unternehmen CYTEK BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,120 (+2,70 %) liegt der Kurs bei 4,560 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.